安晓晋Xiaojin An Ph.D.

顾问

北京 + 86.10.5866.1130 慕尼黑 + 49.89.20.60.42.200

联系：

Share

安晓晋博士主要帮助制药公司，生物技术和诊断技术公司申请和维护其知识产权。她为生命科学领域的公司和风险投资机构就专利方面的问题，例如专利挖掘，授权前景，稳定性、侵权和自由实施问题提供咨询建议，并协助客户开展专利组合尽职调查评估。

安博士在专利申请和布局方面有丰富的经验，涵盖从药物研发早期阶段到后期临床，特别是药物监管部门批准药品上市后专利期限延长的申请，以帮助客户在商业战略和交易中最大化利用知识产权产生价值。

安博士服务包括小型创业公司到大型跨国药企的众多客户。她在抗体，蛋白多肽，疫苗，干细胞，免疫治疗，核酸治疗，诊断方法，基因编辑及精准医疗等技术领域都具有丰富的经验。代表性客户有Celgene Corporation, REGENXBIO, Hookipa Biotech GmbH, Memorial Sloan Kettering Cancer Center, Celularity Inc., Zensun (Shanghai) Sci & Tech Co., Ltd., Gmax Biopharm LLC,等等。

在2013年加入众达之前，安博士在瑞士苏黎世联邦理工学院进行博士后研究，研究方向是寻找癌症病人血液中的小核酸生物标记物，以及探索癌症细胞生存代谢通路。安博士在哈佛大学医学院和北京大学修读博士学位，并获得优秀博士论文奖，以表彰她在低氧诱导的血管新生的基因表达调控及其对于肿瘤和心血管疾病的影响方面的研究工作。安博士更曾在同行评审的一流期刊上发表过八篇研究文章和评论。

经验

  • BMS secures EPO precedential victory on epitope claimsJones Day successfully represented licensee Bristol Myers Squibb’s wholly owned subsidiary Celgene Corporation in the defense of European patent EP 2812443 directed to CD47 antibodies defined by a conformational epitope, in opposition proceedings at the European Patent Office, triggering the first decision that acknowledges patentability of conformational epitope claiming in Europe.
  • Hookipa successfully defends its tri-segmented arenavirus platform technology patent in EPO opposition proceedingsJones Day successfully defended Hookipa Biotech GmbH in opposition proceedings at the European Patent Office.
  • GeneoDx invests in PathoFinderJones Day represented Shanghai GeneoDx Biotech Company Limited, a subsidiary of Sinopharm Group, a leading pharmaceutical company in China, in connection with its investment in PathoFinder Holding B.V. (PFH), which is engaging in molecular diagnostics for the detection of pathogens causing an infectious disease in the Netherlands, by way of purchasing a majority stake in PFH.
  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
    •

    August 2024 Alert

    Epitope Claims Live On at the European Patent Office

    2024年8月 法律快讯

    抗原表位限定的权利要求获得欧洲专利局支持

    November 2023 Commentary

    The EPO Adopts a Patentee-Friendly Approach on Assessing Formal Priority Entitlement

    2023年11月 法律评论

    欧洲专利局在形式优先权裁决中采取了对专利权人友好的做法

    August 2015 Commentary

    Partial Priority and Dealing with "Toxic Divisionals" under the European Patent Convention

    • September 17, 2021
      Patent strategy for Chinese Companies Going Abroad, 6th China Pharma IP Summit
    • October 16, 2020
      Antibody patenting strategy for global protection, 5th China Pharma IP Summit
    • September 25, 2019
      Maximizing protection for your key therapeutic product in Europe.

    发送前请注意

    *Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice